D3 Pharma Limited has announced its continuing partnership with Encap Drug Delivery to expedite the commercial manufacturing and product licensing programme for its proprietary high-dose oral vitamin D3 product, Plenachol™, for the treatment of vitamin D deficiency and insufficiency.
Plenachol™ is a patented liquid-filled capsule formulation of vitamin D3 which was developed in conjunction with Encap and is available at three dose-strengths: 20,000, 40,000 and 100,000 international units.
Plenachol™ has a unique formulation base which is free from animal derived excipients and peanut constituents.
The utility of Encap’s world-class capsule liquid-filling technology secures Plenachol™ as a first and best-in-class high-dose oral vitamin D 3 product.
Plenachol™ will continue to be made available as a Specials product during the pre-license phase via Encap Drug Delivery.
For more information regarding Plenachol™ Specials supply please contact: Dr Janice McLachlan (JMcLachlan@encapdrugdelivery.com).